The glycosylphosphatidylinositol (GPI) anchor attaches nearly 150 proteins to the cell surface. Patients with pathogenic variants in GPI biosynthetic pathway genes display an array of phenotypes including seizures, developmental delay, dysmorphic facial features and cleft palate. There is virtually no mechanism to explain these phenotypes. we identified a novel mouse mutant (cleft lip/palate, edema and exencephaly; Clpex) with a hypomorphic mutation in Post-Glycophosphatidylinositol Attachment to . Pgap2 is one of the final proteins in the GPI biosynthesis pathway and is required for anchor maturation. We found the Clpex mutation results in a global decrease in surface GPI expression. Surprisingly, Pgap2 showed tissue specific expression with enrichment in the affected tissues of the Clpex mutant. We found the phenotype in Clpex mutants is due to apoptosis of neural crest cells (NCCs) and the cranial neuroepithelium, as is observed in the GPI anchored Folate Receptor 1 -/-mouse.. We showed folinic acid supplementation in utero can rescue the cleft lip phenotype in Clpex. Finally, we generated a novel mouse model of NCC-specific total GPI deficiency in the Wnt1-Cre lineage. These mutants developed median cleft lip and palate demonstrating a cell autonomous role for GPI biosynthesis in NCC development.
Introduction
Inherited glycophosphatidylinositol deficiency (IGD) disorders are a class of congenital disorders of glycosylation that affect the biosynthesis of the glycosylphosphatidylinositol (GPI) anchor. The clinical spectrum of IGDs is broad and includes epilepsy, developmental delay, structural brain malformations, cleft lip/palate, skeletal hypoplasias, deafness, ophthalmological abnormalities, gastrointestinal defects, genitourinary defects, heart defects, Hirschsprung's disease, hyperphosphatasia, and nephrogenic defects [1] [2] [3] [4] . However, across all GPI deficiency disorders, the most penetrant defects affect the central nervous system and the craniofacial complex [1] [2] [3] [4] . Indeed, automated image analysis was able to predict the IGD gene mutated in each patient from facial gestalt [2] .
Interestingly, facial gestalt was a better predictor of patient mutation than analysis of the degree of GPI biosynthesis by flow cytometry. Little is known about the mechanism(s) that causes these phenotypes or why disparate tissues are differentially affected [4] [4] .
We sought to determine the mechanism responsible for these phenotypes using a novel mouse model of reduced enzymatic function within the GPI biosynthesis pathway.
The GPI anchor is a glycolipid added post-translationally to nearly 150 proteins which anchors them to the outer leaflet of the plasma membrane and traffics them to lipid rafts [1] . The biosynthesis and remodeling of the GPI anchor is extensive and requires nearly 30 genes [1] . Once the glycolipid is formed and transferred to the C-terminus of the target protein by a variety of Phosphophatidylinositol Glycan (PIG proteins), it is transferred to the Golgi Apparatus for remodeling by Post-GPI Attachment to Proteins (PGAP proteins).
One of these PGAP proteins involved in remodeling the GPI anchor is PostGlycosylphosphatidylinositol Attachment to Proteins 2 (PGAP2). PGAP2 is a transmembrane protein that catalyzes the addition of stearic acid to the lipid portion of the GPI anchor and cells deficient in Pgap2 lack stable surface expression of a variety of GPIanchored proteins (GPI-APs) [1, 5] . Autosomal recessive mutations in PGAP2 cause Hyperphosphatasia with Mental Retardation 3 (HPMRS3 OMIM # 614207), an IGD that presents with variably penetrant hyperphosphatasia, developmental delay, seizures, microcephaly, heart defects, and a variety of neurocristopathies including Hirschsprung's disease, cleft lip, cleft palate, and facial dysmorphia [5] [6] [7] [8] . Currently, there is no known molecular mechanism to explain the cause of these phenotypes or therapies for these patients.
In a forward genetic ENU mutagenesis screen, we previously identified the Clpex mouse mutant with Cleft Lip, Cleft Palate, Edema, and Exencephaly (Clpex) [9] . Here we present evidence that this mutant phenotype is caused by a hypo-morphic allele of Pgap2. To date, embryonic phenotypes of GPI biosynthesis mutants have been difficult to study due to the early lethal phenotypes associated with germline knockout of GPI biosynthesis genes [10] [11] [12] [13] . The International Mouse Phenotyping Consortium labelled Pgap2 homozygote knockout mice preweaning lethal and the Deciphering the Mechanisms of Developmental Disorders initiative labelled Pgap2 homozygotes early lethal as no embryos were recovered at embryonic day E9. 5 . In this study, we took advantage of the Clpex hypomorphic mutant to determine the mechanism of the various phenotypes and tested the hypothesis that GPI-anchored Folate Receptor 1 (FOLR1) is responsible for the phenotypes observed.
As we observed tissue specific defects in NCCs in the Clpex germline mutant, we sought to determine the cell autonomous requirement for GPI biosynthesis pathway generally in NCC development. To do this, we took a conditional approach to abolish GPI biosynthesis in NCCs using the Wnt1-Cre transgene and a floxed allele of a critical initiator of GPI biosynthesis. The Clpex mutant and our NCC conditional mutant serve as models for studying the effect of GPI biosynthesis defects in development of the craniofacial complex and testing potential therapeutics in utero for patients.
Results
The Clpex mutant phenotype is caused by a missense mutation in Pgap2.
We previously identified the Clpex (cleft lip and palate, edema, and exencephaly) mutant in a mouse N-ethyl-N-nitrosourea (ENU) mutagenesis screen for recessive alleles leading to organogenesis phenotypes [9] . Clpex homozygous mutants displayed multiple partially penetrant phenotypes. In a subset of 70 mutants from late organogenesis stages (~E16.5-E18.5), we noted cranial neural tube defects (exencephaly) in 61 (87%), cleft lip in 22 (31%), cleft palate in 13 (19%) , and edema in 6 embryos (9%) (Fig. 1A-H ). Skeletal preparations of Clpex mutants identified a defect in frontal bone ossification (Fig. 1I -L, n=5/5 mutants) and a statistically significant decrease in limb length ( Fig. 1M-P) . We previously reported a genetic mapping strategy with the Mouse Universal Genotyping Array which identified a 44 Mb region of homozygosity for the mutagenized A/J genome on chromosome 7 (Fig. 1Q) [9] . We then took a whole exome sequencing approach and sequenced 3 Clpex homozygous mutants. Analysis of single base pair variants which were homozygous in all 3 mutants with predicted high impact and not already known strain polymorphisms in dbSNP left only one candidate variant (Table 1) . This was a homozygous missense mutation in the initiating methionine (c.A1G, p.M1V) in exon 3 of post-GPI attachment to proteins 2 (Pgap2). We confirmed the whole exome sequencing result by Sanger Sequencing (Fig. 1R ). This mutation abolishes the canonical translation start codon for Pgap2. However, there are alternative start sites of Pgap2 and multiple alternatively spliced transcripts that may lead to production of variant forms of Pgap2.
To determine whether the Clpex phenotype was caused by the missense mutation in as "early lethal" abnormal chorion and trophoblast layer morphology [12] . These data argue Pgap2 is required for early embryogenesis and our Clpex allele must be hypomorphic, as the embryos survive to E18.5.
Pgap2 is dynamically expressed throughout development.
Based on the tissues affected in the Clpex mutant, we hypothesized Pgap2 is expressed in the neural folds and facial primordia of the developing mouse embryo at early stages.
We used the lacZ expression cassette within the Pgap2 null allele to perform detailed expression analysis of Pgap2 throughout development (n= 21 litters at multiple developmental stages). We performed RNA in situ hybridization in parallel for some stages to test the fidelity of the lacZ expression and found high concordance. Pgap2 was expressed relatively uniformly and ubiquitously at neurulation stages in the mouse from E7.5-E8.5 ( Fig. 3A-D) . We also noted extraembryonic expression at E7.5, consistent with the abnormal placental development observed in Pgap2 null/null embryos (Fig. 3A,B ) [12] .
At E9.5-11.5, there was clear enrichment of Pgap2 expression in the first branchial arch ( Fig. 3E-G) . Pgap2 in situ hybridization identified a similar pattern of expression as observed in the Pgap2 LacZ reporter allele at E9.5 ( Fig.3E ) At E10.5 and E11.5, expression was enriched in the limb bud, somites, first branchial arch, eye, forebrain and midbrain ( Fig. 3F-J ). There was also increased expression at the medial aspects of both medial and lateral nasal processes at E10.5 ( Fig. 3G-H) , and strong expression in the heart starting at E11.5 ( Fig. 3I,J) . Later in organogenesis stages, Pgap2 showed more regionalized and enriched expression, including in the ganglion cell layer of the retina at E12.5 and E14.5 ( Fig. 3K,L) . At E16.5 Pgap2 was expressed in the salivary gland, epidermis, stomach, nasal conchae, myocardium, bronchi, kidney, uroepithelium, lung parenchyma, a specific layer of the cortex, and ear ( Fig. 3M-T) . Interestingly, Pgap2
showed lower expression in the liver (Fig. 3S) and most of the brain except for a thin layer of the cortex and the choroid plexus at E16.5 ( Fig. 3S , U-V, X). We also noted expression in the genital tubercle (Fig. 3W ). We conclude Pgap2 shows tissue specific regions of increased expression which may help to explain why certain tissues such as the craniofacial complex, central nervous system, and heart are differentially affected in GPI biosynthesis mutants. These data are in contrast to previous reports where some GPI biosynthesis genes are shown to be ubiquitously and uniformly expressed, including Pign in the mouse and pigu in zebrafish [10, 14] . Our Pgap2 expression is more consistent with the expression of Pigv which is enriched in C. elegans epidermal tissues [15] Pgap2 is required for the proper anchoring of GPI-APs, including FOLR1.
PGAP2 is the final protein in the GPI biosynthesis pathway and catalyzes the addition of stearic acid to the GPI anchor [16] . GPI is a glycolipid added post-translationally to nearly 150 proteins in the endoplasmic reticulum (ER) and remodeled in the Golgi Apparatus.
GPI anchored proteins (GPI-APs) require the GPI anchor for their presentation in the outer leaflet of the plasma membrane and association with lipid rafts [1, 16] . In the absence of Pgap2, cells lack a variety of GPI-APs on the cell surface leading to a functional GPI deficiency [5] [6] [7] [8] 16] . To determine the effect of the Clpex mutation on Pgap2 function, we performed Fluorescein-labeled proaerolysin (FLAER) flow cytometry staining to quantify the overall amount of the GPI anchor on the cell surface. FLAER is a bacterial toxin conjugated to fluorescein that binds directly to the GPI anchor in the plasma membrane. We hypothesized Pgap2 function is impaired in Clpex mutants due to the ENU mutation in the initiating methionine. We found mouse embryonic fibroblasts (MEFs) Current estimates suggest nearly 150 genes encode proteins which are GPI anchored [18] . Our manual review of the MGI database found 102 GPI-APs have been genetically manipulated and phenotyped in mice [19] . Of these, the null allele of Folr1 has a phenotype most similar to the Clpex mutant with cranial neural tube defects, cleft lip/palate, and heart outflow tract phenotypes [20] . 4N ).
Neural crest cells and cranial neuroepithelium display increased apoptosis in the
Clpex mutant.
A number of GPI-APs are critical for cranial neural crest cell (cNCC) migration and survival; including ephrins and FOLR1 [21] [22] [23] [24] [25] [26] [27] [28] [29] . This led us to the hypothesis that cNCC migration may be impaired in Clpex mutants ultimately causing the cleft lip and palate phenotype [22] . To test whether cNCC migration was impaired in the Clpex mutant, we performed a NCC lineage trace using the Wnt1-Cre (B6.Cg-H2afv
Tg ( We observed no significant deficit in cNCC migration in the mutant embryos as compared to littermate controls at either stage (representative images of n=2 E9.5 mutants and n=5 E11.5 mutants) ( Fig. 5A-F ). However, we observed hypoplasia of the medial and lateral nasal processes at E11.5, suggesting the Clpex phenotype is due to earlier defects in NCC survival (Fig 5E-F) . As Pgap2 was highly expressed in the epithelium and epithelial barrier defects are a known cause of cleft palate, we next sought to determine whether the epidermis was compromised in the Clpex mutant [35] . We performed a Toluidine Blue exclusion assay but found no significant defects in barrier formation in the mutant (Fig.   S2 ).
Folr1
-/-mice and zebrafish Folr1 morphants display increased cell death and decreased proliferation in the facial primordia [26, 28, 29, 36] . We hypothesized a similar mechanism may be responsible for the cleft lip and palate in the Clpex mutant embryos. To test this hypothesis, we performed whole mount Nile Blue Sulfate viability staining in WT and homozygous Clpex mutant embryos at E9.5, a stage before we observed hypoplasia of the nasal processes. We found there was an increase in cell death in the facial primordia, including the frontonasal prominence, the first brachial arch, and cranial neuroepithelium Dietary folinic acid supplementation has been shown to rescue the early embryonic lethal phenotype of Folr1 -/-mice and these mice can then survive to adulthood [26, 28, 37] . Our data suggest FOLR1 receptor trafficking is impaired in the Clpex mutant (Fig. 4) , leading us to hypothesize folinic acid supplementation in utero may rescue the Clpex phenotype.
We further hypothesized the folinic acid diet would have a greater beneficial effect as folinic acid (reduced folate) has a higher affinity for other folate receptors including solute carrier family 19 (folate transporter), member 1 (Slc19a1) and solute carrier family 46, member1 (Slc46a1),) which are not GPI anchored [38] . In comparison, folic acid has a higher affinity for the GPI anchored folate receptors FOLR1 and FOLR2 [39, 40] . We supplemented pregnant Clpex dams from E0-E9.5 or E16.5 with a 25 parts per million (ppm) folinic acid diet, 25 ppm folic acid diet or control diet, and collected Clpex mutants for phenotypic analysis and Nile Blue staining for cell viability. We first found folinic acid supplementation decreased the Nile Blue staining for non-viable cells in the facial primordia of E9.5 mutants compared to controls (n=2 mutants; Fig. 6A ,B). We also found the folinic acid diet had an effect on Clpex phenotypes at E16.5. The treatment group had a significantly smaller proportion of mutants with cleft lip (p=0.02) but there was no effect on the incidence of NTD or cleft palate (Fig. 6C,D) . We did note a decrease in mutants with edema, however, this decrease was not statistically significant given our sample size (p=0.06; Fig. 6C,D) . Consistent with our hypothesis, we found the folinic acid reduced the number of mutants with cleft lip by 23% (2/25 mutant vs. 22/70 control), which is more significant than the 10% reduction observed in folic acid treated mice (3/14, Fig. 6C,D) .
Therefore, we conclude folinic acid treatment increased the viability of Clpex facial primordia and decreased the incidence of cleft lip among Clpex mutants.
RNA sequencing reveals changes in patterning genes in Clpex mutants
As folinic acid supplementation could not rescue all phenotypes observed in the Clpex mutant, we took an unbiased transcriptomic approach to determine the major signaling pathway(s) affected upon reduced Pgap2 function. RNA sequencing was performed on pooled RNA samples from wild-type and Clpex homozygous mutant embryos at E9.5 (5 of each in each RNA pool). Sorting differentially expressed genes in ToppGene showed that the most differentially regulated pathways were sequence-specific DNA binding genes including 39 genes (p=1.79x10 -7 ; Table 2 ; [41] ). Among the sequence-specific DNA binding genes, the majority (23/39 genes in the category) were transcription factors which have been implicated in anterior/posterior (A/P) patterning including Cdx2, Cdx4,Tbxt, Hmx1, Lhx2, and Lhx8 [42] [43] [44] [45] [46] [47] [48] [49] (Table 3) . 13 Anterior patterning genes were statistically significantly downregulated and 10 posterior patterning genes were statistically significantly upregulated (Table 2) . We confirmed changes in expression of three of these A/P patterning defects by RNA in situ hybridization at E9.5 (Fig. S3 ). We identified a decrease in Alx3 in Clpex mutants which is both only an anterior patterning gene with a prominent role in frontonasal development and a genetic target of folate signaling [50] .
We investigated Lhx8 because it is expressed in the head at E9.5 and Lhx8 -/-mice develop cleft palate [51] . We found Lhx8 was decreased in Clpex mutant heads. Finally, the master posterior patterning gene Tbxt (brachyury) is critical for determining tail length and posterior somite identity [45, 46] . We found Tbxt was slightly increased in Clpex mutants compared to their overall body size.
The second and third most altered pathways identified by ToppGene were cholesterol transporter activity (p=1.1x10 -6 ), and apolipoprotein binding (p=2.34 x 10 -6
), respectively.
Upon closer inspection, the genes in these categories were largely genes expressed in the mesendoderm including Alpha fetal protein and the Apolipoprotein gene family. We concluded the decreased expression of these genes in the Clpex mutant embryos is consistent with a defect in mesendoderm induction, rather than specific cholesterol and apolipoprotein activities.
Collectively, these findings from our transcriptomic analysis suggest other GPI-Aps involved in A/P patterning and mesendoderm development may be affected in Clpex homozygous mutant embryos. Multiple other mutations in GPI biosynthesis genes including Pgap1 and Pign lead to defective CRIPTO mediated NODAL/BMP signaling which affects the formation of the A/P axis in the early gastrulating embryo [10, 13, 52, 53] . CRIPTO is a co-receptor for NODAL and necessary for the induction of the anterior visceral endoderm and subsequent forebrain and mesendoderm formation [54, 55] . [56, 57] . As we found tissue specific defects in the NCC population in the Clpex mutant, we sought to address a larger question and determine the cell autonomous role for GPI-APs in NCC development.
NCC-specific deletion of Piga completely abolishes GPI biosynthesis and leads to median cleft lip, cleft palate, and craniofacial skeletal hypoplasia
We observed cell type specific apoptosis in the cNCCs in the Clpex mutant and to further our understanding we sought to determine the cell autonomous role of GPI biosynthesis more generally in these cells. Phosphatidylinositol glycan anchor biosynthesis, class A (Piga) is part of the GPI-N-acetylglucosaminyltransferase complex that initiates GPI biosynthesis from phosphatidylinositol and N-acetylglucosamine [1] . Piga is totally required for the biosynthesis of all GPI anchors and Piga deletion totally abolishes GPI biosynthesis [11, 58, 59] . We first performed RNA whole mount in situ hybridization for Piga and showed it has a similar regionalized expression as we observed in the Pgap2 expression experiments. Piga expression at E11.5 is enriched in the first branchial arch, heart, limb, and CNS (representative images from n=8 antisense and 2 sense controls over 3 separate experiments) (Fig. 7A-F) . However, Piga showed a unique enrichment in the medial aspect of both medial nasal processes as opposed to the Pgap2 expression which appeared to line the nasal pit epithelium (Fig. 7C) . Other GPI biosynthesis genes showed a similar regionalization pattern of expression (Fig. S4) .
To determine the NCC specific role for GPI biosynthesis we generated a novel model of These data confirm for the first time a cell autonomous role for GPI biosynthesis in cNCCs during development. As we reduced the amount of Piga from the mosaic cKO to the hemizgous cKO, we observed a worsening of the cleft lip/palate phenotype including more severe hypoplasia of the palatal shelves and widening of the median cleft lip. These data are consistent with the hypothesis that the dosage of GPI biosynthesis is related to the severity of the phenotype with mutants with less residual GPI anchor expression showing more severe phenotypes. Surprisingly, we found hemizygous cKO mutants are capable of forming all the bones and cartilage of the craniofacial skeleton, though they are all hypoplastic.
These data are consistent with the hypothesis that GPI biosynthesis is involved in the survival of early cNCCs as we observed in the Clpex homozygous mutants and not in the later patterning or differentiation of cNCCs. The critical requirement for GPI biosynthesis appears to be at early stages of cNCC survival just after they have migrated from the dorsal neural tube, and before they have committed to differentiation to bone or cartilage.
Discussion
In this study we aimed to determine the role of GPI biosynthesis in craniofacial development with two novel models of GPI deficiency. First, we characterized the phenotype of the ENU-induced Clpex allele which shows partially penetrant cranial neural tube defects, bilateral cleft lip/palate, and edema. We found by mapping and whole exome sequencing the Clpex mutation is a homozygous missense allele in the initiating methionine of Pgap2, the final enzyme in the GPI biosynthesis pathway. Contrary to previous studies of other GPI biosynthesis pathway genes, we found Pgap2 clearly shows enriched expression in certain tissues during certain stages of development. We observed a similar pattern in Piga RNA expression suggesting GPI biosynthesis genes share similar gene enrichment domains. These tissues are the most affected in GPI biosynthesis mouse mutants and include the craniofacial complex, CNS, limb, and heart. This may mean Pgap2 and other GPI biosynthesis genes are required in certain tissues for anchoring GPI-APs critical to that tissue. Alternatively, these areas may be particularly "GPI-rich."
A variety of mutants have been described in the GPI biosynthesis pathway with a wide array of phenotypes [1, 4] . While germline mutants in this pathway remain poorly understood, recent research in Paroxysmal Nocturnal Hemoglobinuria (PNH) caused by somatic mutations in PIGA has revolutionized our understanding of GPI deficiency related pathology. In PNH, clones of GPI deficient hematopoietic stem cells proliferate in the bone marrow and give rise to blood cells that lack GPI-anchored CD55/59 which are required to prevent complement-mediated lysis of red blood cells. PNH patients suffer from episodes of hemolysis and thrombosis which can be deadly [60] . Blockade of complement in these patients via eculizumab, a monoclonal antibody that inhibits the conversion of C5 to C5a, has been shown to greatly improve survival [61] [62] [63] [64] . Thus, a single GPI-AP seems to be largely responsible for the disease observed in these patients.
In this study we aimed to identify a single GPI-AP that could be responsible for all the phenotypes observed in our germline GPI biosynthesis Clpex mutant. Of the known GPI-AP knockout models, Clpex shares the most phenotypic overlap with the Folr1 -/-mouse.
We directly tested the hypothesis that FOLR1 deficiency is solely responsible for the Clpex phenotype by dietary supplementation of folinic acid during embryonic development. To our surprise, folinic acid supplementation could partially rescue the cleft lip phenotype but not the NTD or cleft palate (Fig. 6C,D) . These data also argue high dose folinic acid in utero may be a possible therapeutic for some phenotypes in patients with GPI biosynthesis variants. Further research is required to test whether the positive effect of folinic acid on the Clpex mutants could be observed in other GPI biosynthesis mutants. These data also argue the phenotypes observed in germline Clpex mutants do not share a single mechanism and are not due to the loss of a single GPI-AP. Given the varied response in different tissues to the rescue regimens utilized here, it is likely loss of different GPIMany GPI-APs could be responsible for the phenotypes we observe in the Clpex mutant but were not tested explicitly in this work. Notably, the two receptors for Glial Derived Neurotrophic Factor (GDNF) are GPI-anchored (GFRA1, GFRA2 Clpex mutants [75] . Efna5 -/-mice appear to form DLHPs though the neural folds do not fuse in the midline which is less severe than the defect we observe in Clpex mutants [22] .
Therefore, we find it unlikely the loss of these GPI-APs are primarily responsible for the defects observed in the Clpex mutant although contributions to the phenotype may come from abnormal presentation of one or several of these GPI-Aps on the cellular membranes.
It has been known for decades that treatment of embryos with phospholipase C to release GPI-APs from the cell surface causes NTD in utero [76] . To investigate the cause of the NTD in Clpex mutants, we performed histological and immunohistochemical analysis of the mutant at neurulation stages. We found the Clpex mutant fails to form dorsolateral hinge points and the cranial neuroepithelium is apoptotic in the region of the developing DLHP. Neuroepithelial apoptosis was restricted to the midbrain/hindbrain boundary and likely explains why Clpex mutants develop cranial NTDs as opposed to caudal NTDs such as spina bifida. These cellular defects likely underlie the NTD but the cause of the neuroepithelial apoptosis remains unclear as the NTD did not respond to folinic acid supplementation. It remains controversial, but the NTD in Folr1 -/-mice may be related to an expansion of the Shh signaling domain that patterns the neural tube [36, 77] . Indeed, many Shh gain-of-function mutants develop NTD as Shh expansion impairs the formation of DLHPs and closure of the neural tube [77] . Our RNA sequencing analysis did not identify a dysregulation in the Shh signaling pathway so there are likely differences in the mechanism responsible for the NTD in Folr1 -/-mice and Clpex mutants.
To determine alternative mechanisms responsible for the Clpex phenotype, we performed RNA sequencing from E9.5 WT and Clpex mutants. We found the largest differences in gene expression were in A/P patterning genes and mesendoderm induction genes. The A/P axis and induction of mesendoderm has been shown to require GPI-anchored CRIPTO, a Tgfβ superfamily member co-receptor of NODAL. A variety of studies have shown CRIPTO/Tgfβsuper family members pathway function is impaired in GPI biosynthesis mutants because CRIPTO is GPI-anchored and cleavage of the anchor affects CRIPTO function [10, 52] .
While GPI deficiency has been studied in the context of A/P patterning, this is the first study to implicate GPI biosynthesis in the survival of neural crest cells in a cell autonomous fashion. Indeed, the enrichment of Piga in the developing medial nasal process and the median cleft lip/cleft palate and craniofacial hypoplasia in our Piga cKOs confirms a unique cell autonomous role for GPI biosynthesis in these structures.
Interestingly, these mutants do not show a complete loss of the craniofacial skeleton, rather a general, mild hypoplasia consistent with a role for GPI biosynthesis in early NCC survival, but not later patterning or differentiation.
Our study provides potential mechanistic explanations for the developmental defects observed in a GPI biosynthesis mutant model. We propose GPI biosynthesis is involved in anchoring critical survival factors for NCCs and the neuroepithelium. In GPI deficient states, NCCs undergo apoptosis leading to hypoplastic nasal processes and palatal shelves. As we reduced the degree of GPI biosynthesis from the germline Clpex mutant hypomorph to our totally GPI deficient NCC cKO model, we observed a worsening of the Table S1 . Sample2Snp custom Taqman probes were designed by Thermo-Fisher and used to genotype the point mutation in the Clpex line.
Mapping and Sequencing
Mapping of the Clpex mutation was previously described [9] . Whole exome sequencing was done at the CCHMC DNA Sequencing and Genotyping Core. The Pgap2 exon 3 variant was Sanger sequenced using the Zymo DNA clean & Concentrator kit (Zymo Research Corporation, Irvine, CA).
Whole Mount In Situ Hybridization
RNA in situ hybridization was performed as previously described [78] . Briefly, whole E8-E11.5 embryos were fixed overnight in 4% PFA at 4°C and dehydrated through a methanol series. Samples were treated with 4.5µg/mL Proteinase K for 7-13 minutes at room temperature, post-fixed in 4% PFA/0.2% glutaraldehyde and blocked with hybridization buffer prior to hybridization overnight at 65°C with constant agitation. The samples were washed and incubated with an anti-Dig antibody (Roche #11093274910) o/n at 4°C. Embryos were washed and incubated with NBT/BCIP (SIGMA) or BM Purple (Roche #11442074001) from 4 hours at room temperature to o/n at 4°C .
, and Tbxt (#MR223752) plasmids were obtained from Origene (Rockville, MD). Antisense probes were generated from PCR products containing T3 overhangs. Piga, Pgap2, Pigp, Pigu, Pigx, Lhx8, and Tbxt antisense probes were generated from 910, 750, 556, 952, and 416, 519, and 665 base pair products, respectively. The PCR products were purified, in vitro transcription was performed with digoxigenin-labeled dUTP (Roche #11277073910), and the probe was purified with the MEGAclear Transcription Clean-up kit (Thermo #AM1908) per the manufacturer's instructions. For sense probes, the plasmids were cut with XhoI restriction enzyme after the coding sequence and T7 RNA polymerase was used for in vitro transcription. The Alx3 probe was generated by in vitro transcription of a 790bp PCR product from Alx3 plasmid (DNASU #MmCD00081160) containing T3 overhangs.
MEF/MPNMC production and FLAER staining
MEFs were generated from E13.5 embryos. Embryos were dissected in PBS, decapitated, and eviscerated. The remaining tissue was incubated in trypsin o/n at 4°C
to allow for enzymatic action on the tissue and remaining fibroblasts were passaged in complete DMEM containing 10%FBS and penicillin/streptomycin. MEFs were stained within three passages of their isolation. MEFs and 293T cells were stained with 5µL of Mesenchymal Cells (MPNMCs) were generated from E13.5-E14.5 microdissected embryo heads in a protocol similar to that used for MEPMS [79] . The lower jaw, eyes and brain were removed and the remaining upper jaw and nasal mesenchyme were lysed in 0.25% trypsin for 10 min at 37°C, passaged through a P1000 pipette several times to create a single cell suspension, and cultured in 12 well plates. These cells displayed a stellate mesenchymal cell appearance after culture overnight. They were then stained after 72 hours from isolation with FLAER.
CRISPR Knockout/Knock-in gene editing
We utilized a double guide approach to generate knockout clones with deletions in PGAP2 and PIGA in HEK293T cells. Two small guide RNAs targeting exon 3 of either PGAP2 or PIGA were designed using Benchling software (Benchling, San Francisco, CA) and 5' overhangs were added for cloning into CRISPR/Cas9 PX459M2 puromycinresistance vector [80] . We also generated a single gRNA and donor oligonucleotide for homologous recombination to recapitulate the Clpex mutation in 293T cells (Integrated DNA Technologies ultramer). We cloned these guides into the PX459M2 plasmid using the one-step digestion-ligation with BbsI enzyme as described by Ran et. al. [81] . Two guides per gene were transfected in WT 293T cells using Lipofectamine 3000 and cells 
PGAP2.
Clpex Knock-in clones were Sanger sequenced to identify clones carrying the desired knock-in mutation and clones with indels were discarded. Primers for sgRNA cloning and PCR amplification of targeted regions can be found in Table S1 . Sequencing of clones is presented in Fig. S1 .
Immunofluorescence

293T cells were transfected with FOLR1-myc constructs (Origene #RC212291using
Lipofectamine 3000, incubated for 48 hours, then fixed for 15 min in 4% PFA, and blocked in 4% normal goat serum. They were stained o/n at 4°C with 1:500 rabbit anti-myc (Abcam ab9106), washed the next day and stained with 1:500 488-congugated goat anti-rabbit (Thermo #A11008). They were then stained for 5 min with 5µg/mL wheat germ agglutinin minutes at 37°C to allow for uptake of the dye. They were then washed for 1 hour in PBS at 4°C and immediately visualized.
Histology
Whole embryos E8-E16.5 were fixed in formalin and embedded in paraffin for coronal sectioning and stained with hematoxylin and eosin using standard methods.
NCC lineage trace and Xgal staining
Clpex heterozygous females were crossed to Wnt1-Cre R26R transgenic mice as described in results. Whole embryos were fixed in 4% PFA for 15 minutes at RT, washed in lacZ buffer, and stained in a solution containing 1mg/mL X-gal (Sigma #B4252) [82] .
They were washed 3 times in PBS-T and imaged after several hours in X-gal stain at room temperature.
Diet
Clpex pregnant dams were treated with either control chow, chow + 25ppm folic acid, or chow + 25ppm folinic acid generated by Envigo (Indianapolis, Indiana) from E0-E16.5 ad libitum. They were euthanized at either E9.5 or E16.5 to assess phenotype 
RNA Sequencing
Skeletal Preparation
For skeletal preparation, E16.5-E18.5 embryos were eviscerated and fixed for 2 days in 95% ethanol. They were stained overnight at room temperature in Alcian blue solution (Sigma #A3157) containing 20% glacial acetic acid. They were destained for 24 hours in 95% ethanol and slightly cleared in a 1% KOH solution o/n at room temperature. They were then stained o/n in Alazarin red solution (Sigma #A5533) containing 1% KOH. They were then cleared for 24 hours in 20% glycerol/1%KOH solution. Finally, they were transferred to 50% glycerol/50% ethanol for photographing.
Barrier Function assay
E18.5 embryos were dehydrated through a methanol series and then rehydrated. Next, they were placed in 0.1% Toludine Blue (Sigma #89640) in water for 2 minutes on ice.
They were destained in PBS on ice and imaged.
Statistical Analysis
Statistical analysis was performed using Graphpad Prism (GraphPad Software, San Diego, CA). All tests but diet results were unpaired, two-tailed t-tests and significance was AUTHOR CONTRIBUTIONS. M.L., T.R., P.C., R.W.S. generated and analyzed the data.
M.L. and R.W.S. conceived, designed, and wrote the study. 
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